Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. Issue 2 (February 2012)

• Record Type: Journal Article
• Authors: Ruhlmann, Christina H; Herrstedt, Jørn
• Is Part Of: Expert review of anticancer therapy. Volume 12:Issue 2(2012)
• Page Start: 139
• Page End: 150
• Publication Date: 2012-02
• Subjects: aprepitant -- chemotherapy-induced nausea and vomiting -- fosaprepitant -- MK-0517 -- neurokinin-1 -- receptor antagonist; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/era.11.199
• Languages: English
• ISSNs: 1473-7140

Abstract

For patients receiving cancer chemotherapy, the ongoing development of antiemetic treatment is of significant importance. Patients consider nausea and vomiting among the most distressing symptoms of chemotherapy, and as new antiemetics have been very successful in prevention of vomiting, agents effective against nausea have become one of the major unmet needs. The neurokinin (NK)1 receptor antagonist aprepitant potentiates the antiemetic efficacy of the combination of a serotonin receptor antagonist and a corticosteroid. Fosaprepitant (intravenous prodrug of aprepitant) given as a single intravenous dose of 150 mg can replace the aprepitant 3-day oral regimen. This article focuses on the development and clinical application of fosaprepitant.